AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is conducting an open-label Phase 3 study to evaluate the safety and efficacy of Sodium Zirconium Cyclosilicate (SZC) in pediatric patients with hyperkalaemia. The study aims to assess the ability of SZC to achieve and maintain normal potassium levels in children under 18 years of age. Approximately 140 participants will be enrolled across 46 sites in Europe and North America, with the study divided into three phases: Correction Phase (CP), Maintenance Phase (MP), and Long-term Maintenance Phase (LTMP).
The intervention involves administering SZC, an oral drug, in varying doses based on body weight. The study begins with a Correction Phase where participants receive SZC three times daily until normokalaemia is achieved. Successful participants then move to a 28-day Maintenance Phase with once-daily dosing, followed by an optional Long-term Maintenance Phase.
This single-group study, which started in April 2019, is currently recruiting participants. The study is open-label, meaning there is no masking, and its primary purpose is treatment. Key dates include the study’s start in April 2019, with an estimated completion date in December 2024, and the last update submitted in August 2025.
The clinical study’s progress could positively impact AstraZeneca’s stock performance by demonstrating the drug’s efficacy in a new demographic, potentially expanding its market. This development may also influence investor sentiment favorably, especially if the results show significant benefits over competitors in treating pediatric hyperkalaemia.
The study is ongoing, and further details are available on the ClinicalTrials portal.